The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARWR | +85.6% | -35.06% | -8.27% | -26% |
| S&P | +15.06% | +95.03% | +14.29% | +501% |
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $27.77M | 0.0% |
| Gross Profit | $21.54M | 550.5% |
| Gross Margin | 77.59% | 0.0% |
| Market Cap | $2.18B | -32.4% |
| Market Cap / Employee | $3.58M | 0.0% |
| Employees | 609 | 0.0% |
| Net Income | -$178.65M | -2.7% |
| EBITDA | -$159.33M | 7.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $129.79M | 87.0% |
| Accounts Receivable | $9.70M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $666.28M | 48.7% |
| Short Term Debt | $47.01M | 676.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.11% | 51.0% |
| Return On Invested Capital | -35.41% | -17.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$152.08M | -17.1% |
| Operating Free Cash Flow | -$149.72M | -29.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.28 | 12.61 | 30.42 | 3.19 | -52.13% |
| Price to Sales | 678.45 | 938.86 | 3.14 | 3.83 | -97.67% |
| Price to Tangible Book Value | 7.48 | 13.22 | 35.99 | 3.23 | -52.52% |
| Price to Free Cash Flow TTM | 372.79 | - | |||
| Enterprise Value to EBITDA | -16.45 | -17.09 | 3.50 | -12.60 | -33.65% |
| Free Cash Flow Yield | 0.3% | - | |||
| Return on Equity | -262.5% | -600.7% | -24.7% | -34.8% | -77.53% |
| Total Debt | $851.91M | $872.05M | $740.51M | $713.29M | 57.07% |
ARWR earnings call for the period ending June 30, 2022.
ARWR earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
